Drug-Stocks im Aufwind

 6 Mio auf 0,0015 liegen 

 

http://totallyrealbiotechreport.wordpress.com/

 

FDA 2013 CALENDER AND CLINICAL TRIAL RESULTS—LATEST BIOTECH NEWS STOCK REVIEW UPDATES

April 21th, 2013

Latest Biotech News Stock Review Calls and Forecasts:

Hold tight folks, its gunna be a wild ride: Our biotech tech team, Ronny & StevO, have just spotted BMSN/REGEN team at Pfizer’s Stem cell research facility!  StevO says “its a done deal, we totally saw them signing papers — expect massive blockbuster news this coming week”.  Ronny estimates Bmsn will rise above 10.19$ by June.  Expect a buy out $$$$$$$$$  But why a massive company like Phizer would bother partnering or going into buyout talks with BMSN when they could simply buy a majority stake in BMSN on the open market for a couple of millions dollars is beyond us…  But anyway, REALLY – YOU NEED TO EXPECT A MASSIVE AWESOME PR THIS WEEK FOLKS!!!  

das nächste woche news kommen und das bmsn einer abgeht....?!

 

les mal weiter:

 

DISCLAIMER AND PRIVACY POLICY

 

 

 

 

 

für alle die immer noch nicht an hemaxelleratte glauben...

United States Patent and Trademark Office

http://tsdr.uspto.gov/...seType=SERIAL_NO&searchType=statusSearch

http://tsdr.uspto.gov/...ocId=FTK20130408071115#docIndex=2&page=1

Word Mark  HEMAXELLERATE
Goods and Services IC 001. US 001 005 006 010 026 046. G & S: Biological tissue, namely, blood, stem cells, umbilical cords and placentas for scientific and medical research use
Standard Characters Claimed  
Mark Drawing Code (4) STANDARD CHARACTER MARK
Serial Number 85895235
Filing Date April 4, 2013
Current Basis 1B
Original Filing Basis 1B
Owner (APPLICANT) REGEN BIOPHARMA INC. CORPORATION NEVADA Ste. 304 4700 Spring St. La Mesa CALIFORNIA 91942
Type of Mark TRADEMARK
Register PRINCIPAL
Live/Dead Indicator LIVE

http://tess2.uspto.gov/bin/showfield?f=doc&state=4805:jk9k7o.2.1  

http://www.otcmagic.com/...ic-group-inc-otc-bmsn-sky-high-penny-stock  

down?

Las Vegas, NV -- (SBWIRE) -- 04/22/2013 -- Bio Matrix Scientific Group Inc (PINK:BMSN) dorpped by more than 9 percent to $0.0030 per share in its last trading session.

The stock of Bio Matrix Scientific Group Inc has taken the shape of a bearish beast. The company commenced the trading session at $0 per share. He stock was not at all ignited. The investors supported the stock prices at $0.0029 per share while the stock appeared resistant at $0.0034 per share.

The company however did remarkably well at the recent trading session. 107,958,200 were traded in the recent trading session which is significantly higher than the company’s average volume of 64,609 shares per day. Bio Matrix Scientific Group Inc holds 1.25 billion outstanding shares out of which, 18.19% are held by the insiders of the company.

To know what AwesomePennyStocker projects for Bio Matrix Scientific Group Inc for both long term and short term, please click here: BMSN

AwesomePennyStocker is all about parabolic hot stocks that make epic moves up and reap massive gains for investors. Penny Stocks are heating up and APSR will reports on all of them letting investors know the difference between the winners and the losers. Come visit AwesomePennyStocker for yourself and see what everyone is talking about!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: awesomepennystocker.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://awesomepennystocker.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold awesomepennystocker.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. awesomepennystocker.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. awesomepennystocker.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and awesomepennystocker.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. awesomepennystocker.com, nor any of its affiliates are not registered investment advisors or broker dealers.

http://www.sbwire.com/press-releases/...c-pinkbmsn-is-down-240849.htm  

mal schauen wie sich das entwickelt  

sie doch mal eine Katze aus dem Sack lassen!!  

 Geht in den nächsten 3-4 Wochen auf 10 doller passt auf

 

wie kommst denn darauf, allerdings haben wir heut gar kein umsatz mehr  

entweder, voll down mit starken rebound oder voll hoch....  

Immunotherapy and stem cell technology represent two of the hottest fields in medical science today. Although there is still much research to be done, immunotherapy is seen as the ultimate weapon against some of the most intractable diseases, essentially having the best potential to hunt out and destroy bad cells. And stem cell technology is seen as the best hope for regenerating the body, essentially building more good cells.

But there’s a third less known but no less important component to the future of modern medicine. It’s called pharmacogenomics, a field of study derived from the Human Genome Project. The goal of pharmacogenomics is to provide doctors and researchers the tools necessary to accurately assess genetic variations in patients, and eventually provide drug treatment options that are finely tuned to each patient’s needs, avoiding the trial-and-error approach that doctors are so often forced to rely on. It’s a critical science that could greatly leverage other medical technologies.

Differences in how drugs are metabolized, and their ultimate effects, frequently have a genetic base, and knowing a patient’s genetic makeup could mean the difference between a treatment’s success and failure. When Rainbow Coral Corp. recently announced its plan to partner with a genome-mapping facility in Houston, they were targeting one of the fastest growing segments in biotech, the genetic testing sector, expected to reach $2.2 billion by 2017.

It’s just one of the company’s moves to implement its strategy of developing the best research and drug therapy products. Rainbow also recently acquired a new equity interest in Nano3D Biosciences, an emerging biotech game-changer, whose Bio-Assembler technology may soon allow researchers to dramatically shorten the development timeline for new drugs and treatments, an area that has the potential for explosive growth.

http://blog.qualitystocks.net/2013/04/  

Rainbow Coral Corp. (RBCC) and the New World of Pharmacogenomics
Monday, April 22nd, 2013  

....das runde sümmchen ist jetzt voll.

auch wenn ich blödmann auf 32 erhöht hatte und sie wahrscheinlich für 29 bekommen hätte.

wenn schon untergehen, dann wenigstens mit wehenden fahnen.

 

aber daran glaube ich (noch) nicht wirklich.

 

 

bekommst ein stern von mir :-)

 

 

würd auch gern shoppen aber bin schon am limit

 

... muss doch endlich mal ein ende haben??????!!

 

 

ich versteh nur bahnhof :)  

Woche vorhergesehn keine news und es geht runter auf 0,002X
Regt mich auf das ich bei 0,007$ gekauft hab  

Nachgelesen.... Am 4.4.2013 ging der fda antrag ein ab da 30Tage also muss spätestens am 1-2 mai die news kommen